Search results

26 items
  1. Decriminalization of cannabis

    • Wim van den Brink
    01 March 2008

    This paper discusses the case for decriminalization of cannabis use, based on a careful weighting of the currently available evidence regarding advantages and risks of such a policy change. The issue of decriminalization is a response to the widespread use of cannabis in spite of its current illegal status; that is, as a consequence of the perceived ineffectiveness of the traditional prohibition of cannabis use.

     

  2. Decriminalization of cannabis

    Tom Blickman
    28 March 2008
    Article

    An interesting essay discussing the case for decriminalization of cannabis use appeared in the March 2008 issue of Current Opinion in Psychiatry. The Dutch psychiatrist Wim van den Brink of the Amsterdam Institute for Addiction Research carefully weighs the currently available evidence regarding advantages and risks of such a policy change.

  3. Cannabis Policy: Moving Beyond Stalemate

    • Robin Room, Peter Reuter (RAND), Wayne Hall, Benedikt Fischer, Simon Lenton, Amanda Fielding
    01 September 2008

    Despite cannabis being the most widely used illegal drug, and therefore the mainstay of the ‘war on drugs’, it has only ever held a relatively marginal position in international drug policy discussions. Amanda Fielding of the Beckley Foundation decided to convene a team of the world’s leading drug policy analysts to prepare an overview of the latest scientific evidence surrounding cannabis and the policies that control its use. The report of the Beckley Foundation's Global Cannabis Commission is aimed at bringing cannabis to the attention of policymakers and guide decision making.

     

     

     

  4. Cannabis Use in Canada

    • Benedikt Fischer, Jürgen Rehm, Wayne Hall
    01 March 2009

    Cannabis is the most commonly used illicit drug in Canada, used by 1 in 7 adults and 1 in 4 students. Other forms of drug use (e.g., alcohol or injection drug use) are increasingly approached within a public health policy framework that focuses on reducing harms rather than use per se. Cannabis, by contrast, remains formally controlled by a criminal justice approach that focuses on enforcing abstinence. Its use is associated with a variety of possible acute or chronic health problems that include cognitive and respiratory impairment, psychotic episodes, dependence and injury risk.

     

  5. Thumbnail

    Randomized controlled trial of dexamphetamine maintenance for methamphetamine dependence

    • Marie Longo, Wendy Wickes, Matthew Smout, Sonia Harrison, Sharon Cahill, Jason M. White
    31 May 2009
    Paper

    This study tested the impact of a long-acting form of amphetamine as medication to help control dependent use of the closely allied stimulant, methamphetamine. Prescribed usually for the treatment of pathological sleepiness or attention deficit/hyperactivity disorder, effects of the amphetamine tablets prescribed in the study take several hours longer to emerge than normal amphetamine and last three to six hours longer, giving it a 'smoothing' profile similar to methadone for heroin users; non-rapid onset make it less intensely pleasurable, and longer duration suits it to once-daily administration.

  6. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence

    • Marie Longo, Wendy Wickes, Matthew Smout, Sonia Harrison, Sharon Cahill, Jason M. White
    18 June 2009

    This study tested the impact of a long-acting form of amphetamine as medication to help control dependent use of the closely allied stimulant, methamphetamine. Prescribed usually for the treatment of pathological sleepiness or attention deficit/hyperactivity disorder, effects of the amphetamine tablets prescribed in the study take several hours longer to emerge than normal amphetamine and last three to six hours longer, giving it a 'smoothing' profile similar to methadone for heroin users; non-rapid onset make it less intensely pleasurable, and longer duration suits it to once-daily administration.

     

  7. Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005

    • Martin Frisher, Ilana Crome, Orsolina Martino, Peter Croft
    27 June 2009

    A recent systematic review concluded that cannabis use increases risk of psychotic outcomes independently of confounding and transient intoxication effects. Furthermore, a model of the association between cannabis use and schizophrenia indicated that the incidence and prevalence of schizophrenia would increase from 1990 onwards.

     

  8. Adverse health effects of non-medical cannabis use

    • Wayne Hall, Louisa Degenhardt
    17 October 2009

    For over two decades, cannabis, commonly known as marijuana, has been the most widely used illicit drug by young people in high-income countries, and has recently become popular on a global scale. Epidemiological research during the past 10 years suggests that regular use of cannabis during adolescence and into adulthood can have adverse effects. Epidemiological, clinical, and laboratory studies have established an association between cannabis use and adverse outcomes.

     

  9. Cannabis policy: Time to move beyond the psychosis debate

    • Icaria Editorial
    11 March 2010

    Researchers, research funders and policymakers should give greater voice to the risks and harms associated with particular cannabis policies and to the evaluation of alternative regulatory frameworks. Given the decades of research and experience with cannabis prohibition, it seems reasonable to reorient the cannabis policy debate based on known policy-attributable harms rather than to continue to speculate on questions of causality between cannabis use and mental illnesses such as psychosis, depression, and related disorders, that will not be definitively answered any time soon

     

  10. The changing use and misuse of khat

    • Michael Odenwald, Nasir Warfa, Axel Klein (eds.)
    07 May 2010
    Within the last decade the hitherto little known psychoactive substance of khat has emerged as a regional and international issue. In the Horn of Africa khat production has spurred an economic boom, but dramatic increases in consumption have raised public health concerns. Given the complexity of the topic spanning multiple academic disciplines and fields of professional practice, the need for a systematic overview is urgent.
  11. What should we do about cannabis?

    • Stephen Pudney
    09 November 2010

    No serious commentator doubts that cannabis is potentially damaging to the user. Like tobacco, it is typically smoked and thus shares the potential for lung disease. Like alcohol, it affects reaction times and may raise the risk of road accidents. Cannabis has also been associated with cognitive impairment, deterioration in education performance (van Ours and Williams 2008), and psychotic illness (Arsenault 2004). Moreover, cannabis is often – albeit contentiously – seen as a causal gateway to more serious drug use (Kandel 2002). The question is what to do about it?

     

  12. Marijuana may both trigger and suppress psychosis

    04 January 2012
    Other news

    New research finds that the two main ingredients in marijuana have opposing effects on it. The study examined 15 normal men who had previously smoked cannabis only a few times. Researchers exposed the men to each of the two most psychoactive ingredients in marijuana — delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) and compared their effects with those of a placebo while the participants performed a mental task.

  13. The neuroscience of pot

    Alice G. Walton
    11 January 2012
    Other news

    Marijuana has been shown to have both anxiolytic (anti-anxiety) effects and to induce anxiety and psychosis in certain people. In schizophrenics, it can increase symptoms, and in healthy people it can increase the risk of schizophrenia. Now, new study shows that the two active ingredients in pot, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) may have quite opposite effects on the brain – and behavior – and could explain why pot’s effects can be unpredictable.

  14. Marijuana compound treats schizophrenia with few side effects

    29 May 2012
    Other news

    A compound found in marijuana can treat schizophrenia as effectively as antipsychotic medications, with far fewer side effects, according to a preliminary clinical trial. Unlike the main ingredient in marijuana, THC, which can produce psychotic reactions and may worsen schizophrenia, cannabidiol (CBD) has antipsychotic effects, according to previous research in both animals and humans.

  15. Five biggest lies from anti-pot propagandist Kevin Sabet

    Sunil Kumar Aggarwal
    07 August 2013
    Other news

    Kevin Abraham Sabet-Sharghi, Ph.D., aka Kevin Sabet, has been a headline-grabbing right-winger ever since his U.C. Berkeley days—where he did not study science or medicine despite his current appointment as an assistant professor of medicine at the University of Florida. His most recent incarnation as a co-founder of Project SAM (Smart Approaches to Marijuana) follows a stint in the Obama White House on its drug policy staff from 2009-2011. His personal website claims he is the “quarterback” of a new anti-drug movement, boasting that he’s been “quoted in over 15,000 news stories.”

  16. The city of Utrecht wants to convince mentally ill marijuana users to smoke better pot

    12 September 2013
    Other news

    Thanks in part to the Netherlands' policy of marijuana decriminalization, there are people living in the Dutch city of Utrecht whose addiction to cannabis prevents them from getting effective treatment for mental illness. According to a September 10 statement from Utrecht Mayor Wolfsen, "There is a group of about eighty people with a chronic psychotic disorder who barely respond to their treatment. A possible explanation for this is their severe dependence [on] cannabis."

  17. cannabis-gbd

    The global epidemiology and contribution of cannabis use and dependence to the global burden of disease

    • Louisa Degenhardt et. al.
    23 October 2013

    Cannabis dependence is a disorder primarily experienced by young adults, especially in higher income countries. It has not been shown to increase mortality as opioid and other forms of illicit drug dependence do. Our estimates suggest that cannabis use as a risk factor for schizophrenia is not a major contributor to population-level disease burden.

  18. cannabinoids

    "Think cannabis is harmless?" No. Does anyone?

    Fiona Measham, David Nutt, Josh Hulbert
    23 October 2013
    Other news

    Cannabis is associated with psychosis (a symptom) and schizophrenia (an illness where this symptom is persistent) in complex, contradictory and mysterious ways. The evidence does demonstrate various links that we all should all be aware of, especially cannabis users and parents. However, the evidence does not support anything like the level of fear propagated in the media.

  19. Cigarette smoking 'could make you psychotic'

    12 November 2013
    Other news

    Experts at the Institute of Psychiatry in London are publishing research suggesting that smoking cigarettes may be a contributory cause of schizophrenia (a psychotic disorder). These new findings raise a question - could the most obvious fact about cannabis - that it is usually consumed in combination with tobacco - have been neglected in researching the link between cannabis and psychosis?

  20. Harvard: Marijuana doesn’t cause schizophrenia

    09 December 2013
    Other news

    New research from Harvard Medical School, in a comparison between families with a history of schizophrenia and those without, finds little support for marijuana use as a cause of schizophrenia. “The results of the current study suggest that having an increased familial morbid risk for schizophrenia may be the underlying basis for schizophrenia in cannabis users and not cannabis use by itself,” note the researchers.

Pages